News Gilead to buy immuno-oncology firm Forty Seven for $4.9bn Gilead is to buy immuno-oncology firm Forty Seven for $4.9 billion, adding an antibody targeting several blood cancers to its research pipeline.
Events Partner Content PREDiCT: Imaging Modalities for Oncology Drug Development Guiding Your Strategic Approach of Multimodal Imaging
News GSK begins cancer cell therapy tie-up with Immatics Cancer biotech Immatics has begun a collaboration with GlaxoSmithKline to develop novel therapies built around its T-cell-based technology.
News FDA relents and will review Moderna's flu shot The FDA will start a review of Moderna's flu jab mRNA-1010, after refusing to accept the filing last week, with a new "regulatory approach."
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
